Fintel reports that on November 20, 2025, BTIG upgraded their outlook for AVITA Medical (NasdaqCM:RCEL) from Sell to Neutral.
Analyst Price Forecast Suggests 88.51% Upside
As of November 17, 2025, the average one-year price target for AVITA Medical is $7.45/share. The forecasts range from a low of $3.03 to a high of $14.70. The average price target represents an increase of 88.51% from its latest reported closing price of $3.95 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for AVITA Medical is 59MM, a decrease of 18.73%. The projected annual non-GAAP EPS is -1.22.
What is the Fund Sentiment?
There are 173 funds or institutions reporting positions in AVITA Medical. This is an increase of 1 owner(s) or 0.58% in the last quarter. Average portfolio weight of all funds dedicated to RCEL is 0.01%, an increase of 25.81%. Total shares owned by institutions decreased in the last three months by 26.87% to 6,630K shares. 
The put/call ratio of RCEL is 0.15, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 827K shares representing 2.71% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 674K shares representing 2.21% ownership of the company. In its prior filing, the firm reported owning 675K shares , representing a decrease of 0.18%. The firm decreased its portfolio allocation in RCEL by 34.50% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 389K shares representing 1.28% ownership of the company. No change in the last quarter.
Geode Capital Management holds 331K shares representing 1.09% ownership of the company. In its prior filing, the firm reported owning 618K shares , representing a decrease of 86.55%. The firm decreased its portfolio allocation in RCEL by 74.96% over the last quarter.
FSSNX - Fidelity Small Cap Index Fund holds 266K shares representing 0.87% ownership of the company. In its prior filing, the firm reported owning 264K shares , representing an increase of 0.65%. The firm decreased its portfolio allocation in RCEL by 49.64% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
